Scientific Update
This program will include a discussion of off-label treatments not approved by the FDA for use in the US.
Introduction and Recap
Nonpharmacologic Interventions
Treatment of Bipolar Depression
FDA-Approved Agents for Bipolar Disorder in Children and Adolescents
Impact of Age on Antidepressant-Related Adverse Effects in Youth at Risk for Bipolar Disorder
Antidepressants for Depression Associated With Bipolar Disorder in Youth
Negative Reactions to Antidepressants Among Youth With Bipolar Disorder
Children's Depression Rating Scale
Lithium for Youth With Depression Associated With Bipolar I Disorder: An Open-Label Study
Lamotrigine for Youth With Bipolar Spectrum Disorders: An Open-Label Study
Quetiapine in Youth With Depressive Episodes Associated With Bipolar I Disorder
Quetiapine XR in Youth With Acute Bipolar Depression
OFC for Youth Aged 10 to 17 Years With Bipolar Depression
A Double-Blind, Placebo-Controlled Trial of Lurasidone for Youth With Bipolar Depression
Study Demographics and Primary Outcome Measure: CDRS-R Total Score
Most Common AEs* and Trial Safety Summary
Results of 2-Year Open-Label Study: Efficacy and Safety
Roles of Clinicians and the Community When Managing Pediatric Bipolar Depression
Concluding Remarks
Abbreviations
Abbreviations (cont)